Glomerulonephritis News and Research

RSS

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

7-step guide to understanding tonsils and strep

Fifteen-year-old Kaci Jawegg's family knew the signs and symptoms all too well: It would start with itchy ears, followed by a sore and scratchy throat.

6 Aug 2007

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

QIMR researchers have received a 5 year grant to develop a vaccine against Group A streptococcus

QIMR researchers have received a 5 year grant from the National Institutes of Health in the USA to develop a vaccine against Group A streptococcus. This extremely prestigious grant makes QIMR one of the most successful recipients of NIH funding in Australia.

18 Oct 2004